Aridis Pharmaceuticals Performance
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
The firm shows a Beta (market volatility) of 1.28, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aridis Pharmaceuticals will likely underperform. Aridis Pharmaceuticals right now shows a risk of 0.0%. Please confirm Aridis Pharmaceuticals total risk alpha and the relationship between the potential upside and day typical price , to decide if Aridis Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aridis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental indicators, Aridis Pharmaceuticals is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 20 M |
Aridis |
Aridis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in Aridis Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of 100.00 from holding Aridis Pharmaceuticals or generate -100.0% return on investment over 90 days. Aridis Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Aridis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aridis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aridis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Aridis Pharmaceuticals, and traders can use it to determine the average amount a Aridis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ARDS |
Based on monthly moving average Aridis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aridis Pharmaceuticals by adding Aridis Pharmaceuticals to a well-diversified portfolio.
Aridis Pharmaceuticals Fundamentals Growth
Aridis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Aridis Pharmaceuticals, and Aridis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aridis Pink Sheet performance.
| Return On Asset | -1.08 | ||||
| Operating Margin | (9.58) % | ||||
| Current Valuation | 12.11 M | ||||
| Shares Outstanding | 36.21 M | ||||
| Price To Earning | (1.41) X | ||||
| Price To Book | 5.40 X | ||||
| Price To Sales | 7.33 X | ||||
| EBITDA | (29.51 M) | ||||
| Cash And Equivalents | 6.32 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 6.13 M | ||||
| Debt To Equity | (0.18) % | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (29.13 M) | ||||
| Earnings Per Share | (1.15) X | ||||
| Total Asset | 14.7 M | ||||
| Retained Earnings | (195.67 M) | ||||
| Current Asset | 27.39 M | ||||
| Current Liabilities | 3.06 M | ||||
About Aridis Pharmaceuticals Performance
Assessing Aridis Pharmaceuticals' fundamental ratios provides investors with valuable insights into Aridis Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aridis Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.Things to note about Aridis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Aridis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Aridis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aridis Pharmaceuticals is not yet fully synchronised with the market data | |
| Aridis Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aridis Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (30.37 M) with loss before overhead, payroll, taxes, and interest of (22.61 M). | |
| Aridis Pharmaceuticals currently holds about 6.32 M in cash with (29.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company shares are held by company insiders |
- Analyzing Aridis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aridis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Aridis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aridis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aridis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aridis Pharmaceuticals' pink sheet. These opinions can provide insight into Aridis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |